GenEp, Inc. is a privately held pre-clinical stage biotechnology company based on the licensed intellectual property portfolio of University of Virginia researcher Manoj Patel. GenEp aims to create therapies targeting mutations of sodium and other ion channels that cause rare genetic epilepsies and other treatment-resistant epilepsies.

GenEp, Inc. is the second UVA startup to emerge from the LVG Entrepreneurs in Residence program. Andrew Krouse joins the company as CEO.